Boston Trust Walden Corp Has $46.20 Million Stock Holdings in STERIS plc (NYSE:STE)

Boston Trust Walden Corp boosted its position in shares of STERIS plc (NYSE:STE - Free Report) by 400.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 224,741 shares of the medical equipment provider's stock after acquiring an additional 179,829 shares during the period. Boston Trust Walden Corp owned 0.23% of STERIS worth $46,198,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. West Coast Financial LLC grew its position in STERIS by 2.8% during the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider's stock worth $398,000 after buying an additional 45 shares in the last quarter. Magnolia Capital Advisors LLC increased its holdings in STERIS by 1.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider's stock valued at $521,000 after buying an additional 48 shares during the period. SkyView Investment Advisors LLC increased its holdings in STERIS by 1.6% in the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider's stock valued at $765,000 after buying an additional 51 shares during the period. Park Edge Advisors LLC raised its stake in shares of STERIS by 1.1% in the 4th quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider's stock valued at $958,000 after buying an additional 51 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in shares of STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 76 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on STE. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research note on Friday, November 8th. JMP Securities reiterated a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a research note on Thursday. Piper Sandler raised their target price on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday. Stephens reiterated an "overweight" rating and issued a $240.00 price target on shares of STERIS in a research report on Thursday. Finally, StockNews.com lowered STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $258.75.

STERIS Price Performance

Shares of STE traded down $2.31 on Friday, hitting $223.13. The company's stock had a trading volume of 682,890 shares, compared to its average volume of 519,147. The company has a 50 day moving average price of $212.49 and a 200 day moving average price of $224.60. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The company has a market capitalization of $22.03 billion, a PE ratio of 50.94 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.78% and a net margin of 8.02%. On average, research analysts anticipate that STERIS plc will post 9.11 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.02%. The ex-dividend date is Thursday, February 20th. STERIS's payout ratio is presently 52.05%.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares of the company's stock, valued at $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.14% of the company's stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.